Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Cancer

Date Submitted: May 31, 2024
Date Accepted: Dec 4, 2024

The final, peer-reviewed published version of this preprint can be found here:

Design and Use of Patient-Facing Electronic Patient-Reported Outcomes and Sensor Data Visualizations During Outpatient Chemotherapy

Chen L, Huang W, Li Q, Li Q, Fedor J, Bartel C, Durica KC, Low CA

Design and Use of Patient-Facing Electronic Patient-Reported Outcomes and Sensor Data Visualizations During Outpatient Chemotherapy

JMIR Cancer 2025;11:e62711

DOI: 10.2196/62711

PMID: 39801398

PMCID: 11741193

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Design and Use of Patient-facing ePRO and Sensor Data Visualizations During Outpatient Chemotherapy

  • Leeann Chen; 
  • Weiyu Huang; 
  • Qichang Li; 
  • Qingyang Li; 
  • Jennifer Fedor; 
  • Christianna Bartel; 
  • Krina C. Durica; 
  • Carissa A. Low

ABSTRACT

Background:

Symptoms and side effects change frequently during outpatient cancer treatment. As electronic patient-reported outcome (ePRO) systems used in oncology have become more common, they have been primarily designed to collect symptoms from patients and shared with providers without making the data collected available to patients. The goal of this study was to develop and evaluate ePRO and sensor data visualizations that patients could access online during chemotherapy.

Objective:

The goal of this study was to develop and evaluate patient-facing ePRO and sensor data visualizations that patients could access online during chemotherapy.

Methods:

As part of an ongoing NCI-funded study to develop a remote symptom monitoring system, we created mobile-friendly web visualizations of daily symptom ratings, wearable data and self-management resources, available to patients undergoing chemotherapy. At the end of the three month study, 141 patients completed a survey.

Results:

Survey respondents were heterogenous in age (M 61 years old, range 29- 92 years old), race (80%, 113/141 white, 20%, 28/141 other) and cancer stage (56%, 75/135 Stage IV). About half (54%, 76/141) of participants accessed the link to their data visualizations. There were no significant differences between the participants who did and did not click the link during the study in terms of average age (P =.74), gender (P =.66), race (P =.50) or cancer stage (P =.31) . Of those who accessed the platform, most (54%, 41/76) viewed it a few times, while 13% (10/76) used it daily. Most (77%, 58/75) believed it was “Somewhat” or “Very Helpful/Informative.” All ten daily users joined the study within three months of starting chemotherapy for the first time.

Conclusions:

Findings suggest that patients new to chemotherapy may be most interested in viewing visualizations of daily symptom and sensor data and that the web application is widely accessible for patients of different ages, races, and cancer stages.


 Citation

Please cite as:

Chen L, Huang W, Li Q, Li Q, Fedor J, Bartel C, Durica KC, Low CA

Design and Use of Patient-Facing Electronic Patient-Reported Outcomes and Sensor Data Visualizations During Outpatient Chemotherapy

JMIR Cancer 2025;11:e62711

DOI: 10.2196/62711

PMID: 39801398

PMCID: 11741193

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.